Latest Vascular endothelial growth factor Stories
New Insights, Discoveries and Interim Clinical Data on Generx® Phase 3 Angiogenic Therapy for Patients with Cardiac Microvascular Insufficiency and Coronary Artery Disease SAN DIEGO,
TARRYTOWN, N.Y., Jan. 23, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- DIG-KT is a novel bi-specific mAb targeting VEGFR2 and Tie-2 pathways for treating cancers SHENYANG, China and DAEJEON, South Korea, Jan. 14, 2015 /PRNewswire/ -- 3SBio Inc.
DALLAS, December 15, 2014 /PRNewswire/ -- ReportsnReports.com adds Ocular Disorders: Rising Therapeutics, Technologies, and Devices 2014 market research report that covers
With Americans spending billions of dollars each year on nutritional supplements, researchers have analyzed popular eye vitamins to determine whether their formulations and claims are consistent with scientific findings.
Research shows that, of 11 popular supplements analyzed, 7 do not adhere to proven formulas; all 11 have misleading claims SAN FRANCISCO, Dec.
Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Lpath, Inc.
Treatment of Visual Impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) and Diabetic Macular Edema (DME) are the Second and Third Indications for Eylea(®) in Canada
TARRYTOWN, N.Y., Dec. 1, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.
CRESTWOOD, Ky., Nov. 20, 2014 /PRNewswire/ -- Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.